AJANTA PHARMA Latest Share Price (AJANTPHARM)
TODAY IN ONE LINE
AJANTPHARM edged up 0.4% on light volume, in line with Nifty's -0.3% move.
With a market cap of ₹44,190.36 Cr., it trades at a P/E of 38.94. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
AJANTA PHARMA flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 18.6% YoY
- ●High Capital EfficiencyROCE of 23.1% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 23.3%
- ●Healthy Operating MarginsOPM is structurally strong at 25.6%
- ●High Promoter HoldingPromoters hold 63.5% skin-in-the-game
- ●Steady Dividend YieldReliable 1.70% dividend yield
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.05x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
Red Flags
- ●Promoter SellingPromoter holding decreased by 2.77% QoQ
- ●Promoter Pledging DetectedPledge activity recorded on 2026-06-05
Latest AJANTA PHARMA News
What changed recently?
Recent events, corporate actions, and announcements.
AJANTA PHARMA valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for AJANTA PHARMA, framed against the sector median so the premium or discount is obvious at a glance.
AJANTA PHARMA trades at a P/E of 38.94× and P/B of 9.76×, against the Healthcare sector median P/E of 41.12×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
AJANTA PHARMA technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for AJANTA PHARMA — derived from the latest tape, not yesterday's close.
AJANTA PHARMA last traded at ₹3,533.4 with an intraday range of ₹3,460–₹3,560 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹3533.40| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 3775.60 | +242.20 | +6.85% |
| R3 | 3675.60 | +142.20 | +4.02% |
| R2 | 3617.80 | +84.40 | +2.39% |
| R1 | 3575.60 | +42.20 | +1.19% |
| PIVOT | 3517.80 | -15.60 | -0.44% |
| CURRENT | 3533.40 | — | — |
| S1 | 3475.60 | -57.80 | -1.64% |
| S2 | 3417.80 | -115.60 | -3.27% |
| S3 | 3375.60 | -157.80 | -4.47% |
| S4 | 3275.60 | -257.80 | -7.30% |
AJANTPHARM is trading Above CPR, indicating Bullishness
CPR is Average
Day's range: ₹3461–₹3516
Trading Inside opening range
AJANTA PHARMA financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for AJANTA PHARMA — consolidated or standalone — with margins, YoY growth and key ratios inline.
AJANTA PHARMA reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹44,190.36 Cr. and reported EPS of ₹26.75.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 4,648 | 5,453 ▲ 17.3% |
| Sales Growth YoY %Derived | 10.44% | 17.31% |
| Other Income | 95 | 172 ▲ 82.1% |
| Total Income | 4,743 | 5,625 ▲ 18.6% |
| 1,071 | 1,184 ▲ 10.6% | |
| Gross ProfitDerived | 3,577 | 4,269 ▲ 19.3% |
| Gross Margin %Derived | 76.96% | 78.29% |
| 2,318 | 2,874 ▲ 24.0% | |
| EBITDA (Operating Profit)Derived | 1,260 | 1,395 ▲ 10.7% |
| OPM %Derived | 27.10% | 25.58% |
| 165 | 189 ▲ 14.8% | |
| Profit Before Tax (PBT) | 1,189 | 1,378 ▲ 15.9% |
| 269 | 322 ▲ 19.7% | |
| Effective Tax %Derived | 22.60% | 23.35% |
| Total Profit for Period | 920 | 1,056 ▲ 14.7% |
| Net Profit (Owner's PAT)Derived | 920 | 1,056 ▲ 14.7% |
| Net Profit Margin %Derived | 19.80% | 19.37% |
| PAT Growth YoY %Derived | 12.77% | 14.73% |
| Earnings Per Share (EPS ₹) | 73.68 | 84.52 ▲ 14.7% |
| Diluted Shares Outstanding (Cr) | 12 | 12 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | 2 | 29 ▲ 1471.9% |
| Total Expenses (incl. D&A & Interest) | 3,553 | 4,247 ▲ 19.5% |
| Material Cost % of RevenueDerived | 18.21% | 16.81% |
| Employee Cost % of RevenueDerived | 23.44% | 23.68% |
| Other Cost % of RevenueDerived | 26.42% | 29.03% |
| Interest Coverage (x)Derived | 53.81x | 75.83x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 2,131 | 2,055 ▼ 3.5% | 2,588 ▲ 25.9% | 2,890 ▲ 11.7% | 3,341 ▲ 15.6% | 3,743 ▲ 12.0% | 4,209 ▲ 12.5% | 4,648 ▲ 10.4% | 5,453 ▲ 17.3% | |
| Sales Growth YoY %Derived | — | -3.54% | 25.91% | 11.66% | 15.62% | 12.02% | 12.45% | 10.44% | 17.31% | |
| Other Income | 24 | 21 ▼ 12.7% | 92 ▲ 337.3% | 26 ▼ 71.8% | 116 ▲ 345.3% | 99 ▼ 14.7% | 85 ▼ 14.2% | 95 ▲ 11.7% | 172 ▲ 82.1% | |
| Total Income | 2,155 | 2,076 ▼ 3.6% | 2,680 ▲ 29.1% | 2,916 ▲ 8.8% | 3,457 ▲ 18.6% | 3,841 ▲ 11.1% | 4,293 ▲ 11.8% | 4,743 ▲ 10.5% | 5,625 ▲ 18.6% | |
406 | 383 ▼ 5.6% | 656 ▲ 71.0% | 645 ▼ 1.6% | 832 ▲ 29.0% | 1,050 ▲ 26.2% | 1,067 ▲ 1.5% | 1,071 ▲ 0.4% | 1,184 ▲ 10.6% | ||
| Gross ProfitDerived | 1,724 | 1,672 ▼ 3.0% | 1,932 ▲ 15.6% | 2,245 ▲ 16.2% | 2,509 ▲ 11.8% | 2,692 ▲ 7.3% | 3,142 ▲ 16.7% | 3,577 ▲ 13.9% | 4,269 ▲ 19.3% | |
| Gross Margin %Derived | 80.93% | 81.34% | 74.66% | 77.68% | 75.09% | 71.93% | 74.66% | 76.96% | 78.29% | |
1,066 | 1,105 ▲ 3.7% | 1,249 ▲ 13.0% | 1,246 ▼ 0.2% | 1,579 ▲ 26.8% | 1,909 ▲ 20.9% | 1,970 ▲ 3.2% | 2,318 ▲ 17.6% | 2,874 ▲ 24.0% | ||
| EBITDA (Operating Profit)Derived | 658 | 566 ▼ 14.0% | 683 ▲ 20.6% | 999 ▲ 46.1% | 929 ▼ 6.9% | 783 ▼ 15.7% | 1,172 ▲ 49.6% | 1,260 ▲ 7.5% | 1,395 ▲ 10.7% | |
| OPM %Derived | 30.90% | 27.56% | 26.41% | 34.56% | 27.82% | 20.93% | 27.85% | 27.10% | 25.58% | |
60 | 73 ▲ 22.1% | 104 ▲ 41.6% | 124 ▲ 19.9% | 136 ▲ 9.0% | 137 ▲ 0.8% | 143 ▲ 4.4% | 165 ▲ 15.6% | 189 ▲ 14.8% | ||
| Profit Before Tax (PBT) | 623 | 514 ▼ 17.4% | 664 ▲ 29.1% | 900 ▲ 35.6% | 909 ▲ 1.0% | 745 ▼ 18.1% | 1,114 ▲ 49.5% | 1,189 ▲ 6.8% | 1,378 ▲ 15.9% | |
154 | 127 ▼ 17.3% | 196 ▲ 54.2% | 246 ▲ 25.5% | 197 ▼ 20.1% | 157 ▼ 20.1% | 298 ▲ 89.3% | 269 ▼ 9.7% | 322 ▲ 19.7% | ||
| Effective Tax %Derived | 24.72% | 24.75% | 29.56% | 27.36% | 21.64% | 21.10% | 26.73% | 22.60% | 23.35% | |
| Total Profit for Period | 469 | 387 ▼ 17.4% | 468 ▲ 20.9% | 654 ▲ 39.8% | 713 ▲ 9.0% | 588 ▼ 17.5% | 816 ▲ 38.8% | 920 ▲ 12.8% | 1,056 ▲ 14.7% | |
| Net Profit (Owner's PAT)Derived | 469 | 387 ▼ 17.4% | 468 ▲ 20.9% | 654 ▲ 39.8% | 713 ▲ 9.0% | 588 ▼ 17.5% | 816 ▲ 38.8% | 920 ▲ 12.8% | 1,056 ▲ 14.7% | |
| Net Profit Margin %Derived | 21.99% | 18.83% | 18.07% | 22.63% | 21.33% | 15.71% | 19.39% | 19.80% | 19.37% | |
| PAT Growth YoY %Derived | — | -17.43% | 20.86% | 39.81% | 8.99% | -17.50% | 38.81% | 12.77% | 14.73% | |
| Earnings Per Share (EPS ₹) | 35.50 | 29.57 ▼ 16.7% | 35.73 ▲ 20.8% | 50.38 ▲ 41.0% | 55.62 ▲ 10.4% | 45.89 ▼ 17.5% | 64.82 ▲ 41.3% | 73.68 ▲ 13.7% | 84.52 ▲ 14.7% | |
| Diluted Shares Outstanding (Cr) | 13 | 13 ▼ 0.9% | 13 ▲ 0.0% | 13 ▼ 0.8% | 13 ▼ 1.3% | 13 ▲ 0.0% | 13 ▼ 1.7% | 12 ▼ 0.8% | 12 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | 4 | -3 ▼ 187.3% | 6 ▲ 272.1% | -6 ▼ 216.0% | -8 ▼ 23.6% | 15 ▲ 286.3% | 1 ▼ 94.5% | 2 ▲ 128.4% | 29 ▲ 1471.9% | |
| Total Expenses (incl. D&A & Interest) | 1,532 | 1,562 ▲ 1.9% | 2,016 ▲ 29.1% | 2,015 ▼ 0.0% | 2,547 ▲ 26.4% | 3,096 ▲ 21.5% | 3,179 ▲ 2.7% | 3,553 ▲ 11.8% | 4,247 ▲ 19.5% | |
| Material Cost % of RevenueDerived | 17.75% | 19.06% | 21.65% | 24.45% | 23.33% | 23.47% | 22.32% | 18.21% | 16.81% | |
| Employee Cost % of RevenueDerived | 17.67% | 20.96% | 18.76% | 18.97% | 19.33% | 20.98% | 21.39% | 23.44% | 23.68% | |
| Other Cost % of RevenueDerived | 32.36% | 32.83% | 29.49% | 24.15% | 27.95% | 30.03% | 25.42% | 26.42% | 29.03% | |
| Interest Coverage (x)Derived | 1,460.49x | 426.16x | 49.34x | 106.71x | 78.82x | 111.72x | 143.76x | 53.81x | 75.83x |
AJANTA PHARMA segment analysis : revenue and profit mix.
Disclosed business segments at AJANTA PHARMA with their share of revenue and profit, switchable between consolidated and standalone reporting.
AJANTA PHARMA discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for AJANTA PHARMA.
Our AI distills the core fundamental drivers supporting AJANTA PHARMA, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
AJANTA PHARMA's investment case rests on 0 positive markers and 1 flagged concerns drawn from the latest reported filings.
What you're getting.
No strengths or opportunities on record.
Key Risks.
SWOT generation temporarily unavailable due to model error. Bedrock invocation timeout
Flip Conditions.
Valuation risk. a P/E above 51 (~1.2× the sector multiple of 41.1) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 18% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 0.85%.
AJANTA PHARMA peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — AJANTA PHARMA is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
AJANTA PHARMA chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for AJANTA PHARMA — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
AJANTA PHARMA delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for AJANTA PHARMA over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in AJANTA PHARMA stood at 54.8% of traded volume, against a 20-day average of 50.2%.
AJANTA PHARMA announcements: results, concalls, ratings, M&A.
Filings AJANTA PHARMA sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
AJANTA PHARMA files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 105 documents below.
Analysts/Institutional Investor Meet/Con. Call Updates
Ajanta Pharma Limited has informed the Exchange about
Copy of Newspaper Publication
Ajanta Pharma Limited has informed the Exchange about Copy of Newspaper Publication
Analysts/Institutional Investor Meet/Con. Call Updates
Ajanta Pharma Limited has informed the Exchange about Participation in Investor Conference
Analysts/Institutional Investor Meet/Con. Call Updates
Ajanta Pharma Limited has informed the Exchange about Transcript
Copy of Newspaper Publication
Ajanta Pharma Limited has informed the Exchange about Copy of Newspaper Publication
AJANTA PHARMA dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue AJANTA PHARMA has declared, sequenced by announce and record date.
AJANTA PHARMA corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
AJANTA PHARMA insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in AJANTA PHARMA as reported to SEBI — buying and selling signals from the people who know the business best.
AJANTA PHARMA insider activity below tracks 7 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| SHAILESH R SINGH | Insider | 12 Mar 2026 | buy | +607 | ₹18.82 L | ₹3,100.18 |
| SHAILESH R SINGH | Insider | 12 Mar 2026 | buy | +607 | ₹18.82 L | ₹3,100.18 |
| SHAILESH R SINGH | Insider | 12 Mar 2026 | buy | +607 | ₹18.82 L | ₹3,100.18 |
| VANDANA SHAILESH SINGH | Insider | 27 Feb 2025 | sell | −548 | ₹14.92 L | ₹2,722.45 |
| J K TRIPATHI | Insider | 30 Dec 2024 | sell | −100 | ₹2.95 L | ₹2,950.00 |
| J K TRIPATHI | Insider | 18 Dec 2024 | sell | −100 | ₹2.9 L | ₹2,895.00 |
| J K TRIPATHI | Insider | 29 Nov 2024 | sell | −100 | ₹3 L | ₹3,000.00 |
About AJANTA PHARMA: business, sector, key facts.
What AJANTA PHARMA does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
AJANTA PHARMA operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: AJANTPHARM, BSE: 532331.
Ajanta Pharma Limited is a pharmaceutical company specializing in the development, manufacturing, and marketing of finished dosage forms of specialty pharmaceuticals. Their product portfolio encompasses both chronic and acute therapies, primarily focusing on branded generic medications. This means they produce medications similar to brand-name drugs once their patents expire, but under their own branding, allowing them to offer more affordable options to consumers.
The company's manufacturing capabilities are diverse, covering a wide range of dosage forms. These include common formats like tablets and capsules, but also extend to more specialized delivery methods such as injectables, inhalers, and topical applications in the form of ointments, creams, and liquids. This broad range of delivery methods allows Ajanta Pharma to cater to a wide variety of medical needs and patient preferences.
Ajanta Pharma's therapeutic focus spans several key areas of healthcare. Their products address conditions related to cardiology (heart health), dermatology (skin conditions), ophthalmology (eye care), and pain management. This strategic focus on specific therapeutic areas allows them to develop expertise and build a strong reputation within those markets.
The company maintains a significant global presence, operating across multiple continents. Their markets include India, where they are headquartered, as well as extensive operations in Africa and Asia. Furthermore, they have established a presence in the United States, a major pharmaceutical market, demonstrating a commitment to international expansion and a broad reach within the global healthcare landscape.
Founded in 1973 and headquartered in Mumbai, India, Ajanta Pharma has a long history in the pharmaceutical industry. Their continued success is likely driven by their diverse product portfolio, comprehensive manufacturing capabilities, focus on key therapeutic areas, and significant global reach. The company's commitment to producing high-quality, affordable medications suggests a continued focus on providing access to essential healthcare worldwide.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- ALBERT DAVID (ALBERTDAVD) Share PricePeer
- Top quality scorecard stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about AJANTA PHARMA (AJANTPHARM).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of AJANTA PHARMA (AJANTPHARM)?
The current share price of AJANTA PHARMA (AJANTPHARM) is ₹3,533.40. Today, the stock has gained by ₹13.40 (0.38%), trading in a range of ₹3,460.00 to ₹3,560.00. The stock opened at ₹3,516.00 with a trading volume of 45,547 shares.
02Is AJANTA PHARMA stock a good investment for long-term?
AJANTA PHARMA can be considered for long-term investment based on several factors. The company has a market capitalization of ₹44,190.36 Cr., P/E ratio of 38.94, ROE of 23.33%, and ROCE of 23.05%. The dividend yield stands at 1.7%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of AJANTA PHARMA stock?
The 52-week high price of AJANTA PHARMA (AJANTPHARM) is ₹3,796.00, while the 52-week low is ₹2,329.90. Currently trading at ₹3,533.40, the stock is 51.65% above its 52-week low and 6.92% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy AJANTA PHARMA stock at the current price?
Whether to buy AJANTA PHARMA stock at ₹3,533.40 depends on multiple factors. The stock is currently trading with a P/E ratio of 38.94 and P/B ratio of 9.76. Today's performance shows a gain of 0.38%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of AJANTA PHARMA and when is the next dividend?
AJANTA PHARMA offers a dividend yield of 1.7%, which means for every ₹100 invested at the current price of ₹3,533.40, you can expect to receive approximately ₹1.70 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of AJANTA PHARMA?
AJANTA PHARMA's key financial metrics include: P/E Ratio: 38.94, P/B Ratio: 9.76, ROE: 23.33%, ROCE: 23.05%, Dividend Yield: 1.7%, EPS: ₹26.75, Book Value: ₹362.35, and Debt-to-Equity: 0.05. The company's market cap stands at ₹44,190.36 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is AJANTA PHARMA stock performing today in the market?
AJANTA PHARMA stock opened at ₹3,516.00 and is currently trading at ₹3,533.40, showing a gain of ₹13.40 (0.38%). The intraday high is ₹3,560.00 and low is ₹3,460.00. The trading volume stands at 45,547 shares, indicating moderate market participation today.
08What is the P/E ratio of AJANTA PHARMA and what does it indicate?
AJANTA PHARMA has a Price-to-Earnings (P/E) ratio of 38.94, which means investors are willing to pay 38.94 for every ₹1 of earnings. With an EPS of ₹26.75, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about AJANTA PHARMA (AJANTPHARM) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.